Prof. Magnus Ingelman-Sundberg
Professor of Molecular Toxicology since 1996 and research group leader in Pharmacogenetics at the Department of Physiology and Pharmacology since 2006, Karolinska Institute since 2006. Vice Chairman and Section Head.
His research has one focus on dedifferentiation and differentiation of hepatocytes studied with respect to genomic and epigenomic changes. One of the aims of his study is to create fully functional hepatocytes from stem cells. His lab has developed a new 3D hepatocyte in vitro system having a proteome very similar to the liver the hepatocytes originate from and where the functionality remains for > 5 weeks, a system suitable for studies of liver diseases, drug target validation, drug metabolism and chronic drug toxicity. The regulation of the genome and epigenome in the 3D liver models is studied in response to steatosis, fibrosis, hepatitis and drug treatment. He developed a novel drug therapy for colon cancer treatment using a cancer specific drug target (CYP2W1) in collaboration with chemists and surgeons. He also identify new genetic and epigenetic factors that constitute pharmacogenomic biomarkers for individualization of drug treatment.
Had published more than 440 original papers, 24,000 citations (30,000 in Google Scholar) and an h-factor of 83 (ISI) or 97 (Google Scholar).
He is a member of The Nobel Assembly
at Karolinska Institute since 2008 and member of Faculty of 1,000 Biology
since 2006. He is also a member of Editorial Advisory Boards of many leading scientific journals in the field.
Recently categorized by Thomson Reuters as one of the World’s Most Influential Scientific Minds
) based on recent (2002-2012) citations from highly ranked papers. (Top 1% cited in the field of pharmacology).
Dr. Mahendra S Rao, MD, PhD
Dr. Mahendra is a researcher known for his work involving human embryonic stem cells and other somatic stem cells. Rao received his MD from Bombay University, India, and then earned a PhD in developmental neurobiology from California Institute of Technology.
After postdoctoral work at Case Western Reserve, he became an independent researcher at University of Utah. Next he joined the National Institute of Aging, where he studied neural progenitor cells and their potential clinical use. Dr. Rao was also the VP of Regenerative Medicine at Life Technologies. Additionally, he co-founded Q Therapeutics, a stem-cell research firm and serves on USDA Cellular Tissue and Gene Therapies advisory committee and more. Rao also holds a joint research appointment in NIAMS and NINDS. In 2011, Rao was appointed Director of the National Institute of Health Center for Regenerative Medicine. He published more than 200 scientific articles in leading journals.
Dr. Yaqub Hanna
Dr. Hanna earned a BSc in Medical Sciences, an MSc in Microbiology and Immunology, and a PhD/MD in clinical medicine, all at the Hebrew University of Jerusalem, where he was among the top five percent of all Israeli medical school graduates. He conducted postdoctoral research at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He joined the Weizmann Institute in 2011.
Dr. Hanna is pioneering techniques in induced pluripotency and reprogramming of adult cells. He was the lead researcher in a study that showed how further-modified IPS cells could be used to treat sickle-cell anemia in mice, the first proof of concept of the therapeutic application of IPS. He published 60 scientific articles in leading journals.